| Drug ID: | Drug40 |
|---|---|
| Drug Name: | Dexamethasone |
| CID: | 5743 |
| DrugBank ID: | DB01234 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT03456752, , NCT00152620 |
| Molecular Formula: | C22H29FO5 |
| Molecular Weight: | 392.5 g/mol |
| Isomeric SMILES: | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C |
| Synonyms: | dexamethasone; 50-02-2; Hexadecadrol; Aeroseb-Dex; Fluormethylprednisolone; Desametasone; Superprednol; Visumetazone; Cortisumman; Decaderm |
| Phase 0: | 45 |
| Phase 1: | 588 |
| Phase 2: | 1315 |
| Phase 3: | 812 |
| Phase 4: | 645 |
| Description: | An anti-inflammatory 9-fluoro-glucocorticoid. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt363 | 5743 | Dexamethasone | 1544 | CYP1A2 | Homo sapiens (human) | None | |
| dt364 | 5743 | Dexamethasone | 3726 | JUNB | Homo sapiens (human) | None | |
| dt365 | 5743 | Dexamethasone | 2168 | FABP1 | Homo sapiens (human) | None | |
| dt366 | 5743 | Dexamethasone | 1559 | CYP2C9 | Homo sapiens (human) | None | |
| dt367 | 5743 | Dexamethasone | 23047 | PDS5B | Danio rerio (zebrafish) | 27941970 | Dexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of PDS5B mrna] |
| dt368 | 5743 | Dexamethasone | 3651 | PDX1 | Rattus norvegicus (Norway rat) | Dexamethasone results in decreased expression of PDX1 mRNA | |
| dt369 | 5743 | Dexamethasone | 109731405 | PDXDC2P | Homo sapiens (human) | 28628672 | [INS protein co-treated with dexamethasone co-treated with 1-methyl-3-isobutylxanthine co-treated with indomethacin co-treated with bisphenol A] results in decreased expression of PDXDC2P mrna|[ins protein co-treated with dexamethasone co-treated with 1-m |
| dt370 | 5743 | Dexamethasone | 283970 | PDXDC2P-NPIPB14P | Homo sapiens (human) | 25047013 | Dexamethasone results in decreased expression of PDXDC2P-NPIPB14P mRNA |
| dt371 | 5743 | Dexamethasone | 8566 | PDXK | Homo sapiens (human) | 28628672 | [INS protein co-treated with dexamethasone co-treated with 1-methyl-3-isobutylxanthine co-treated with indomethacin co-treated with bisphenol A] results in decreased expression of PDXK mrna|[ins protein co-treated with dexamethasone co-treated with 1-meth |
| dt372 | 5743 | Dexamethasone | 791775 | pdxka | Danio rerio (zebrafish) | 27941970 | Dexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of PDXKA mrna] |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT03456752 | Perioperative Dexamethasone on Postoperative Outcome in IBD | PHASE2 | COMPLETED | Jinling Hospital, China | Inflammatory Bowel Diseases; Dexamethasone; Posto… | DRUG: Dexamethasone; DRUG: Normal saline | Details |
| NCT00152620 | Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease | None | TERMINATED | University of Chicago | Inflammatory Bowel Disease (IBD) | DRUG: Dexamethasone|DRUG: Methylprednisolone | Details |
| NCT03723447 | A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel): the TINGLE Trial | PHASE4 | Not recruiting | Cedars-Sinai Medical Center | Pain, Postoperative;Crohn Disease;Inflammatory Bo… | Drug: Liposomal bupivacaine;Drug: Bupivacaine/epi… | Details |
| NCT01171807 | Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis | PHASE2 | COMPLETED | Quince Therapeutics S.p.A. | Ulcerative Colitis | DRUG: Dex 21-P|DRUG: Placebo | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Dexamethasone-Induced MerTK(+/high) M2c Macrophages Exhibit a Preference for Do…
PMID: 40206211
Year: 2025
Relationship Type:
Treatment
Score: 6.5
In a prior study, adoptive cell transfer (ACT) of Dexamethasone (DEX)-induced M2c macrophages with positive expression of MerTK receptor mitigated ac…
Dexamethasone Upregulates the Expression of the Human SLC26A3 (DRA, Down-Regula…
PMID: 39657154
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Down-Regulated in Adenoma (DRA) plays a critical role in intestinal chloride absorption and a decrease in its expression is a key event i…
Design of colon-targeted drug delivery of dexamethasone: Formulation and in vit…
PMID: 39100451
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Colon-targeted drug delivery continues to generate increasing attention for its prospects in treating inflammatory bowel disease (IBD). This study ai…
Ionically bridged dexamethasone sodium phosphate-zinc-PLGA nanocomplex in algin…
PMID: 37537405
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Colon-targeted oral drug delivery systems comprising nanoparticles and microparticles have emerged as promising tools for the treatment of ulcerative…
Design and characterization of dexamethasone loaded microsponges for the manage…
PMID: 37061099
Year: 2023
Relationship Type:
Mechanism
Score: 6.5
Ulcerative colitis is an inflammatory condition with ulcerations throughout the colon. The existing remedies have some limitations such as drug inact…
Mucoadhesive Nanoparticles Enhance the Therapeutic Effect of Dexamethasone on E…
PMID: 36718245
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: As the first-line drug to treat ulcerative colitis (UC), long-term use of glucocorticoids (GCs) produces severe toxic and side effects. L…
In Vitro and In Vivo Evaluation of Hydroxypropyl-β-cyclodextrin-grafted-poly(ac…
PMID: 36422529
Year: 2022
Relationship Type:
Mechanism
Score: 6.5
In this paper, we fabricated semi-interpenetrating polymeric network (semi-IPN) of hydroxypropyl-beta-cyclodextrin-grafted-poly(acrylic acid)/poly(vi…
Bacterioruberin from Haloarchaea plus dexamethasone in ultra-small macrophage-t…
PMID: 32208325
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Oral administration of antioxidant and anti-inflammatory drugs have the potential to improve the current therapy of inflammatory bowel disease. Succe…
Epigenetic Alterations Associated With Early Prenatal Dexamethasone Treatment
PMID: 30623163
Year: 2018
Relationship Type:
Treatment
Score: 6.3
Prenatal treatment with dexamethasone (DEX) reduces virilization in girls with congenital adrenal hyperplasia (CAH). It has potential short- and long…
Dramatic resolution of disseminated pyoderma gangrenosum associated with monocl…
PMID: 28371346
Year: 2017
Relationship Type:
Treatment
Score: 6.3
Pyoderma gangrenosum (PG) is an uncommon inflammatory and ulcerative skin disorder, which is commonly associated with systemic conditions such as inf…
Efficacy of Setarud (IMod), a novel drug with potent anti-toxic stress potentia…
PMID: 21174949
Year: 2010
Relationship Type:
Treatment
Score: 6.1
The inflammatory bowel disease (IBD) is an idiopathic, immune-mediated and chronic intestinal condition. In the present study, the effect of Setarud …
Biological and diurnal variation in glucocorticoid sensitivity detected with a …
PMID: 20463096
Year: 2010
Relationship Type:
Association
Score: 6.1
INTRODUCTION: Glucocorticoid resistance due to mutations of the glucocorticoid receptor (NR3C1) are rare, but reduced glucocorticoid sensitivity may …